Pacini F, Elisei R, Anelli S, Gasperini L, Schipani E, Pinchera A
Institute of Endocrinology, University of Pisa, Italy.
Int J Biol Markers. 1986 May-Aug;1(2):85-8. doi: 10.1177/172460088600100205.
The utility of determining circulating neuron-specific enolase (NSE) in medullary thyroid carcinoma was assessed in 25 patients followed up for a mean period of 45.6 months. In 5 patients tested before any treatment serum NSE concentrations were in the normal range. After total thyroidectomy abnormally high serum NSE concentrations (more than 9.8 ng/ml) were found in 1/3 patients with normal calcitonin (CT) in remission, in 2/10 with elevated CT levels but no evidence of disease and in 9/12 with elevated CT levels and documented metastases. The mean (+/- SD) NSE value in this last group was 12.0 +/- 12.6 ng/ml, significantly higher than in the other groups (p less than 0.005). The time course of serum NSE in patients with long follow-up seems to indicate that serum NSE rises when a large tumor mass is present and usually parallels the pattern of circulating CT. Effective treatment of the metastases is usually followed by reduction of serum NSE. Thus, serum NSE can serve as an additional humoral marker for medullary thyroid carcinoma, its elevation being associated with important metastatic involvement and with a poor prognosis of the tumor.
对25例平均随访45.6个月的甲状腺髓样癌患者测定循环神经元特异性烯醇化酶（NSE）的效用进行了评估。在5例任何治疗前检测的患者中，血清NSE浓度在正常范围内。全甲状腺切除术后，在1/3降钙素（CT）正常且病情缓解的患者、2/10 CT水平升高但无疾病证据的患者以及9/12 CT水平升高且有记录转移的患者中发现血清NSE浓度异常升高（超过9.8 ng/ml）。最后一组的平均（±标准差）NSE值为12.0±12.6 ng/ml，显著高于其他组（p<0.005）。长期随访患者的血清NSE时间进程似乎表明，当存在大肿瘤块时血清NSE升高，且通常与循环CT模式平行。转移灶有效治疗后血清NSE通常会降低。因此，血清NSE可作为甲状腺髓样癌的一种额外体液标志物，其升高与重要的转移累及和肿瘤的不良预后相关。
